DS
EPIX

David Shaw’s ESSA Pharma EPIX Stock Holding History

David Shaw’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-62,955
Closed -$382K – 4508
2024
Q3 		$382K Sell
62,955
-526
-0.8% -$2.89K ﹤0.01% 3857
2024
Q2 		$334K Sell
63,481
-1,600
-2% -$10.2K ﹤0.01% 3833
2024
Q1 		$553K Sell
65,081
-134,572
-67% -$1.17M ﹤0.01% 3431
2023
Q4 		$1.32M Buy
199,653
+31,603
+19% +$156K ﹤0.01% 2950
2023
Q3 		$519K Hold
168,050
– – ﹤0.01% 3416
2023
Q2 		$454K Sell
168,050
-4,171
-2% -$12.2K ﹤0.01% 3460
2023
Q1 		$511K Sell
172,221
-78,164
-31% -$230K ﹤0.01% 3545
2022
Q4 		$631K Sell
250,385
-249,448
-50% -$716K ﹤0.01% 3728
2022
Q3 		$910K Buy
499,833
+159,207
+47% +$420K ﹤0.01% 3660
2022
Q2 		$1.07M Buy
340,626
+39,834
+13% +$223K ﹤0.01% 3587
2022
Q1 		$1.86M Buy
300,792
+166,278
+124% +$1.46M ﹤0.01% 3375
2021
Q4 		$1.91M Sell
134,514
-181,217
-57% -$2.02M ﹤0.01% 3391
2021
Q3 		$2.53M Buy
+315,731
New +$5.02M ﹤0.01% 2816

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

David Shaw's EPIX Position: Q4 2024 in Review

David Shaw sold out of ESSA Pharma (EPIX) in Q4 2024, closing a stake of 62,955 shares — an estimated $382K sold.

David Shaw first reported a position in EPIX in Q3 2021 and held it in 13 quarters. The position peaked at $2.53M in Q3 2021. 46 funds tracked by Wall St. Rank hold EPIX as of Q4 2024.

  • David Shaw reported no remaining ESSA Pharma position as of Q4 2024 after selling out during the quarter.
  • David Shaw sold 62,955 ESSA Pharma shares in Q4 2024, an estimated $382K.
  • David Shaw first reported a position in ESSA Pharma in Q3 2021 and held it in 13 quarters.
  • David Shaw's ESSA Pharma position peaked at $2.53M in Q3 2021.
  • 46 funds tracked by Wall St. Rank held ESSA Pharma as of Q4 2024.

Based on D.E. Shaw & Co's 13F filing for Q4 2024, filed 14 Feb 2025.